Allena Pharmaceuticals Inc (NASDAQ:ALNA)’s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as $6.62 and last traded at $6.91, with a volume of 46300 shares changing hands. The stock had previously closed at $6.91.

ALNA has been the subject of a number of recent research reports. Wedbush initiated coverage on shares of Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating and a $30.00 price objective for the company. Credit Suisse Group initiated coverage on shares of Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating and a $22.00 price objective for the company. ValuEngine upgraded shares of Allena Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Cowen initiated coverage on shares of Allena Pharmaceuticals in a research note on Monday, November 27th. They issued an “outperform” rating for the company. Finally, Jefferies Group initiated coverage on shares of Allena Pharmaceuticals in a research note on Monday, November 27th. They issued a “buy” rating and a $22.00 price objective for the company. Two research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $24.67.

The firm has a market capitalization of $130.22 and a P/E ratio of -6.12. The company has a debt-to-equity ratio of -0.09, a quick ratio of 4.83 and a current ratio of 4.83.

Allena Pharmaceuticals (NASDAQ:ALNA) last announced its quarterly earnings data on Thursday, December 14th. The company reported ($3.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($3.11). equities analysts predict that Allena Pharmaceuticals Inc will post -0.89 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp bought a new stake in shares of Allena Pharmaceuticals in the 4th quarter worth about $102,000. Dean Capital Investments Management LLC bought a new stake in shares of Allena Pharmaceuticals in the 4th quarter worth about $116,000. BlackRock Inc. bought a new stake in shares of Allena Pharmaceuticals in the 4th quarter worth about $2,281,000. Sphera Funds Management LTD. bought a new stake in shares of Allena Pharmaceuticals in the 4th quarter worth about $3,270,000. Finally, Frazier Management LLC bought a new stake in shares of Allena Pharmaceuticals in the 4th quarter worth about $33,504,000. 0.07% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Allena Pharmaceuticals (ALNA) Sets New 52-Week Low at $6.62” was originally posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://theolympiareport.com/2018/02/14/allena-pharmaceuticals-alna-sets-new-52-week-low-at-6-62.html.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.